Background. In post-traumatic stress disorder (PTSD) there is a need for self-rating scales that are sensitive to treatment effects and have been tested in a broad range of trauma survivors. Separate measures of frequency and severity may also provide an advantage.
INTRODUCTION
Post-traumatic stress disorder (PTSD) was first included in the Diagnostic and Statistical Manual of Mental Disorders, 3rd edition (DSM-III), in 1980 (American Psychiatric Association, 1980) . Since then, several different rating scales have been introduced to measure PTSD. These scales are typically clinician administered and thus limited by requiring the time and expertise of a qualified interviewer. Examples of clinicianadministered rating scales include the Structured Interview for PTSD (SI-PTSD) (Davidson et al. 1989) , the Clinician Administered PTSD Scale (CAPS) (Blake et al. 1990) , and the Structured Clinical Interview for DSM-III-R (SCID) (Spitzer et al. 1990) . Although several self-rating scales exist in the literature, including the Impact of Event Scale (IES) (Horowitz et al. 1979) , Mississippi Scale (Keane et al. 1988) , Penn Inventory (Hammarberg, 1992) , PTSD Inventory (Solomon et al. 1993) and PTSD Symptom Scale (Foa et al. 1993) , these are all limited because reliability and validity have not been demonstrated in widely ranging populations. The IES, which has been adopted as a standard self-rating instrument, pre-dates DSM-III and fails to incorporate hyperarousal symptoms, an important component of the PTSD symptom complex. Moreover, none of the above selfrating scales separately addresses frequency and severity of symptoms.
We have developed the Davidson Trauma Scale (DTS), a self-rated scale tailored closely to the symptom definitions of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (American Psychiatric Association, 1994 ). The DTS is designed to evaluate symptoms of PTSD in individuals with a history of trauma. Its primary purposes are to measure symptom frequency and severity and to evaluate treatment, for example, measurement of symptom change over time, response prediction, and evaluation of differences between therapy modalities in the research setting. In this report, we present data on reliability and validity of the scale. We have administered the DTS to over 300 subjects from separate clinical research studies of rape, combat and natural disaster, as well as a sample of mixed trauma survivors participating in a double-blind, placebocontrolled pharmacotherapy study of PTSD. We evaluated the following measures of reliability and validity : test-retest reliability, internal consistency, and factorial, concurrent, convergent, discriminant and predictive validity.
METHOD Subjects
We administered the DTS to 353 subjects who had taken part in one of four clinical research studies. Seventy-eight women participated in a study of rape victims (Study 1), 110 men in a Mean agep.. 2 6 n 4 p 6 n 9 4 6 n 7 p 7 n 7 4 0 n 8 p 12n7 4 4 n 7 p 7 n 4 Gender  Male  0  110  11  84  Female  78  0  42  18   Marital status  Married  20  73  33  Not available  Not married  58  37  20   Race  Caucasian  66  66  36  Not available  Other  12  44  17 study of war veterans (Study 2), 53 subjects in a study of Hurricane Andrew victims (Study 3), and 102 subjects in a multicentre clinical trial of an antidepressant drug in survivors of miscellaneous traumas (Study 4). Table 1 presents demographic breakdowns for the four samples. Each of these studies rendered some shared and some unique data, depending upon the measures involved (described below).
Davidson Trauma Scale
The DTS is composed of 17 items corresponding to each of the 17 DSM-IV symptoms. Items can be categorized as follows : items 1-4, 17 : criteria B (intrusive re-experiencing) ; items 5-11 : criteria C (avoidance and numbness) ; and items 12-16 : criteria D (hyperarousal). For each item, the subject rates both frequency and severity during the previous week on a 5-point (0 to 4) scale for a total possible score of 136 points. Subscale scores can be computed separately for frequency and severity.
Other clinical measures
In addition to the DTS, subjects were assessed with several other scales useful for assessing validity. For concurrent validity, the SCID was administered as an independent validator. Positive and negative predictive value, sensitivity, specificity, and efficiency were determined. We also examined DTS scores as a function of ratings on the physician-rated Global Assessment of Severity (GASP) (Katz, 1995, personal communication) . For convergent validity with other quantitative PTSD scales, the DTS total score was compared with total scores of both the CAPS and the IES, as well as with the subscales, index score, and total score of the SCL-90-R (Derogatis, 1977) . The Eysenck Personality Inventory Extroversion scale (Eysenck & Eysenck, 1968 ) was compared with the DTS to evaluate discriminant validity, as a null relationship was expected between the two measures. Finally, the Clinical Global Impressions (CGI) Improvement scale (Guy, 1976 ) was used to assess sensitivity to treatment effects and predictive validity.
Statistical analysis
Internal consistency was evaluated using Cronbach's α. Test-retest reliability and convergent and discriminant validity were assessed using Pearson product-moment correlations. Factorial validity was examined using exploratory factor analyses. Concurrent validity was assessed by comparing DTS scores of patients with and without SCID PTSD diagnoses via t test. Sensitivity, specificity, predictive value, efficiency and area under the curve were calculated according to standard formulae (Baldessarini et al. 1983 ; Hanley & McNeil, 1982) . Also, an analysis of variance (ANOVA) was used to compare DTS scores in relation to five severity categories assigned using the GASP. Sensitivity to treatment effects was examined using a general linear models (GLM) analysis, with CGI Improvement category as a grouping variable and time (treatment baseline and endpoint) as a repeated measure. Predictive validity was evaluated by regressing DTS scores against CGI Improvement ratings. Subsamples utilized for particular analyses are reported in pertinent results sections.
RESULTS

Test-retest reliability
Test-retest reliability was examined by comparing the baseline total DTS score with a DTS assessment two weeks later in subjects from the multicentre clinical trial who had been rated with ' no change ' on the CGI Improvement scale (N l 21). The test-retest reliability coefficient was 0n86 (P 0n0001).
Internal consistency
Cronbach's α was used to evaluate internal consistency of the DTS in 241 patients recruited from the rape-victims study, the war veterans, and the study of Hurricane Andrew victims. For the 17 frequency and severity items, the coefficient was 0n99 ; for the frequency items alone it was 0n97 and for the severity items alone it was 0n98.
Factorial validity
Principal-components factor analysis of data from studies 1-3 (N l 241) revealed the presence of two main factors, one of which accounted for over 20 % of the variance (eigenvalue l 24n19) and is interpreted as a severity factor. The second factor, with an eigenvalue of 1n34, accounted for a small amount of variance. This factor largely consisted of positive loadings on intrusive items and negative loadings on avoidance and numbing items (Table 2) . When factor analysis was conducted using only subjects with a current PTSD diagnosis (N l 67), six factors were retained, with eigenvalues of 18n88, 2n44, 1n98, 1n45, 1n14 and 1n02 (Table 3) . Factor I was a general severity factor, with loadings for each item ranging from 0n56 to 0n84. Factor II loaded on reduced enjoyment, estrangement, lack of loving feelings, and foreshortened future. Factor III contained two items with positive loadings, avoiding doing things and insomnia, along with negative loadings for being emotionally upset by reminders. Factor IV also loaded on insomnia, as well as frequency of avoiding thoughts, feelings, and situations reminiscent of the event. Factor V loaded negatively on hyperarousal symptoms of irritability, hypervigilance and exaggerated startle response. Factor VI loaded positively on frequency of amnesia for important aspects of the event and negatively on distressing dreams and frequency of foreshortened future.
Concurrent validity
SCID diagnoses were used to assess concurrent validity. One hundred twenty-nine subjects were administered the SCID. These came from the rape-victims study, the study of war veterans and the Hurricane Andrew study. Sixty-seven of these subjects met a SCID diagnosis of current PTSD. These subjects had a meanp.. total DTS score of 62n0p38n0, whereas those who did not meet current PTSD criteria (N l 62) displayed significantly lower scores : 15n5p13n8 (t l 9n37, P 0n0001).
Sensitivity, specificity, predictive value and efficiency were calculated for all possible DTS scores relative to a SCID-based diagnosis of PTSD as independent validator according to the definitions of Insel & Goodwin (1983) . Table 4 shows five different threshold scores and their corresponding sensitivity (percentage with PTSD scoring at threshold or higher), specificity (percentage without PTSD scoring below threshold), predictive value of a positive test (percentage scoring at or above threshold who have PTSD), predictive value of a negative test (percentage scoring below threshold who do not have PTSD), and efficiency (percentage correctly classified as having PTSD or as not having PTSD). The highest efficiency was found at a total score of 40. The area under the curve (pstandard error) was 0n88 (p0n02).
A self-rated scale which purports to assess symptom severity can also be evaluated relative to an independent severity measure. Such a marker was used in the multicentre clinical trial, wherein the GASP provided a 15-point rating of severity, ranging from 1-3 (minimal, within the range of normality), 4-6 (subclinical PTSD), 7-9 (clinical PTSD), 10-12 (severe PTSD) and 13-15 (very severe PTSD). Specific descriptors of each category were given to raters. Treatment endpoint scores were used as opposed to baseline measures because the former provided a greater distribution of severity. Mean DTS total scores for each GASP category were as follows : minimal (N l 17), 14n0p13n8 ; subclinical (N l 27), 41n7p28n1 ; clinical (N l 36), 78n5p27n1; 17  0n90  0n60  0n65  0n88  0n73  27  0n81  0n82  0n78  0n84  0n81  36  0n70  0n90  0n86  0n79  0n81  40  0n69  0n95  0n92  0n79  0n83  48  0n57  0n99  0n97  0n74  0n80 severe (N l 15), 108n5p15n4 ; very severe (N l 2), 114n0p8n4. An ANOVA revealed highly significant differences between these five groups (F (%,*#) l 42n7, P 0n0001).
Convergent and discriminant validity
To assess convergent validity with other PTSD rating scales, we compared the DTS total score with the CAPS and IES total scores. Subjects from studies 1 and 2 (N l 102) were included in this analysis. The correlations were 0n78 (P 0n0001) for the CAPS and 0n64 (P 0n0001) for the IES. With reference to the IES, we further parsed the DTS into three subsections cor- responding to re-experiencing\intrusions, avoidance\numbness and hyperarousal. The IES avoidance subsection correlated 0n52 (P 0n0001) with the DTS numbness\avoidance items. The IES intrusion subsection correlated 0n77 (P 0n0001) with the DTS reexperiencing\ intrusion items. As another measure of convergent validity, 123 subjects from the rape-victims and Hurricane Andrew studies completed the SCL-90-R. The total score, subscales, and index score were each correlated with the DTS total score. Results, presented in Table 5 , revealed significant correlations between total DTS score and each of the SCL-90-R scales, with the highest association noted for the anxiety subscale.
The Eysenck Personality Inventory Extroversion subscale was correlated with the DTS total score to evaluate discriminant validity. The resulting coefficient was 0n04 (NS).
Predictive validity
To evaluate predictive validity, baseline DTS total scores were examined in relation to endpoint CGI ratings in Study 4 to explore whether initial severity on the DTS predicted response to double-blind treatment. Subjects rated at endpoint as very much improved (N l 26) scored 63n5p28n6 ; those much improved (N l 24) scored 84n5p26n0 ; minimally improved (N l 22) 84n9p25n9 ; no change (N l 13) 84n5p26n1 ; minimally to markedly worse (N l 12) 94n3p29n0. A regression analysis examining CGI response predicted by baseline DTS score revealed a significant positive relationship (P 0n005), although the R# was low (0n10).
Sensitivity to treatment effects
Sensitivity to treatment effects was evaluated by comparing the DTS total score in responders versus non-responders to the double-blind medication trial (Study 4). Response was defined as an endpoint CGI score of 1 or 2 ; non-response was defined as a CGI score of 3 or greater. A significant interaction was observed between responder status and DTS totals at baseline and endpoint (F (",*&) l 31n75, P 0n0001). The 50 CGI responders had mean DTS total scores of 73n6p29n1 and 40n3p32n9 at baseline and endpoint, respectively, whereas the 47 CGI nonresponders had mean scores of 87n2p26n5 and 85n8p32n1 , respectively.
DISCUSSION
The DTS was developed as a self-rating scale measuring frequency and severity of each DSM-IV symptom of PTSD in subjects having identified an unusually traumatic event, or set of events. The intrusive and avoidant items are asked with reference to the event, while the numbing, withdrawal and hyperarousal items are rated as present or absent without direct linking to the event -a slight departure from the DSM-IV and the CAPS, which require these symptoms to have arisen after the event. We judged that the ability of a subject to make an accurate assessment in this respect after either remote childhood trauma or chronic and persistent re-traumatization would be difficult. This point of view receives some support from the study of Solomon & Canino (1990) , which demonstrated poor reliability of patient descriptions of such symptomatology. Because of this slight departure from the way in which DSM-IV symptoms are assessed, and because the DTS does not explicitly refer to avoided conversation as an example of avoidance, we do not present the DTS as a diagnostic instrument. However, it appears to be useful as a symptomseverity measure, as a predictor and measure of treatment response, and as a diagnostic ally, in that its diagnostic efficiency reached 83 %. As designed, the scale likewise fulfilled standard criteria for reliability and validity in a broad range of adult trauma victims.
Diagnostic assessment using the DTS, relative to the SCID, yielded respectable accuracy. At a score of 40, the positive predictive value, negative predictive value, and efficiency of 0n92, 0n79 and 0n83 were comparable to values for the Penn Inventory of 0n84, 0n92 and 0n86 and for the Mississippi Scale of 0n88, 0n87 and 0n88 (Hammarberg, 1992) . While diagnostic efficiency of these latter scales was slightly higher, their values were based upon a more restricted trauma sample.
Factor analysis of the sample as a whole revealed that the factor structure of the DTS did not correspond to the group clusters of DSM-IV (i.e. intrusive, avoidant\numbing and hyperarousal). A single factor accounted for much of the variance and may be construed as a severity measure or a higher-order organizing factor. A second, smaller factor emerged consistent with intrusive symptoms. In yielding primarily a single higher-order factor, the DTS is similar to the combat Mississippi Scale (Keane et al. 1988) and different from our earlier report of the SI-PTSD (Davidson et al. 1989 ) and the self-rated civilian version of the Mississippi Scale (Vreven et al. 1995) . When factor analysed in the subsample of subjects with current PTSD, a general severity factor emerged, along with numbing (factor II), avoidance\insomnia and absence of intrusion (factors III and IV), and hyperarousal symptoms (factor V). These principal factors are more in keeping with the DSM formulation of symptom groupings in PTSD.
The DTS performed well as a measure detecting change over time during a controlled treatment study, as well as yielding a statistically significant prediction of treatment outcome. The latter finding, that is, that more severely symptomatic PTSD responded less well to a pharmacotherapy trial, echoes an earlier finding with amitriptyline, in which we found that higher baseline Hamilton anxiety and depression scores (Hamilton, 1959 (Hamilton, , 1960 were associated with poorer response on the CGI (Davidson et al. 1993) . Also of relevance was the correlation in that study between high baseline PTSD symptoms and poor outcome measured by the self-rated IES.
The DTS was validated mostly against scales which either predated or were modelled after DSM-III-R. In ideal circumstances, DSM-IV analogues would have been preferred, but they were unavailable at the time. We, nevertheless, believe that the DTS offers a useful new assessment option for the following reasons. The sample in which we have tested the DTS is perhaps the most comprehensive of all used to evaluate PTSD symptom-severity scales, with victims of both sexes drawn from four different trauma groups (rape, combat, hurricane and a category of miscellaneous other traumata). We also provided an assessment of the scale in a controlled treatment-trial setting. One of the main purposes of the DTS is to measure PTSD severity and to detect treatment change over time. We believe our results demonstrate promise in this regard. Moreover, in unpublished data from our own group, the DTS proved to be more sensitive at detecting drug versus placebo differences than the IES, CGI or SI-PTSD in a double-blind trial. We can also adduce construct validity for the DTS relative to a biological marker of PTSD, namely, rapid eye movement (REM) density, as measured by polysomnography in the hurricane survivors. Severity of intrusive symptoms correlated significantly with REM density in a subsample of Study 3 (Mellman et al. 1995) .
Further work remains in relation to the DTS, including developing and applying it to other populations (e.g. children, non-English speakers), additional investigation of its factor structure, and assessment of its ability to detect differences between active medication and placebo.
